The Korea-Seoul Life Science Fund (KSLSF) is a cross-border venture capital fund that invests in innovative life sciences companies. Our area of investment is broad within all sectors of life sciences, including biotechnology, drugs, medical devices, diagnostics, healthcare services and healthcare convergence. We invest in early- through growth stage companies that develop differentiated and category-defining products.

We understand that pathways toward building successful companies are dynamic and require creative flexibility and unwavering conviction along the way. This justifies our investment in the capabilities and integrity of the founders and management of the companies.

Our geographical focus includes Asia and the U.S. In technologically connected world where physical mobility of talented entrepreneurs is ever so increasing, we believe that innovation and great companies can be found across different geographies. In particular, cross-Pacific interplay is fast becoming a critical growth driver for the life sciences industry. 

KSLSF is strategically positioned and uniquely operated to partake in this promising trend. We have offices in Boston and Seoul.

 

TEAM

Our core team collectively has multiple decades of experience in the life sciences investment management, pharmaceutical operations and scientific research. In addition to our core team, KSLSF’s Entrepreneur-in-Residence and Advisors are highly accomplished leaders who have had important impact in their respective fields.

Core Team

B. Christopher Kim, Ph.D.

Managing Partner

Dr. Kim is the Managing Partner of KSLSF and a Partner of Oxford Bioscience Partners.  He is responsible for all aspects of investment, portfolio support and Fund operations of KSLSF.  Dr. Kim’s investments include PharmAbcine (member of BOD, mAb therapies for cancer), Pathway Genomics (personalized genetic testing, San Diego), and CrystalGenomics (KOSDAQ listed, small molecules to treat inflammation, infection and cancer). Prior to KSLSF and OBP , Dr. Kim served as Associate Director and Head of Operations for the global BioMarker Development group at the Novartis Institutes for BioMedical Research.  He held an additional role in corporate development and strategy while at Novartis.  Previously, Dr. Kim was a member of the IBM Extreme Blue program, providing strategic direction for IBM HealthCare and Life Sciences .  At Alkermes, he conducted preclinical pharmacology research to evaluate proprietary drug delivery systems.  Throughout his career, Dr. Kim has been engaged by VC firms and biotech companies as their advisor or consultant.  He is a Special Advisor of Extera Partners, a Cambridge-based investment bank specialized in life sciences transactions. Dr. Kim received an MBA from Carnegie Mellon University where he was President of the BioPharma Business Club.  Dr. Kim obtained a Ph.D. in Biomedical Sciences from the University of Texas Health Science Center and the MD Anderson Cancer Center with a focus on developmental biology, and a BA in Economics and BS in Biology from the University of California at Irvine.  Dr. Kim authored a number of peer-reviewed scientific publications in the areas of preclinical pharmacology, and developmental biology. E-mail

Jonathan J. Fleming

General Partner

Mr. Fleming is a General Partner of KSLSF. He is also President and Treasurer of NEHI, a national health care policy think tank. Founded in 2002, NEHI is a nonprofit, non-partisan, evidence-based institute dedicated to identifying innovations that provide solutions to the most pressing issues facing our health care system today.  Since 1999, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, Massachusetts.  Mr. Fleming has been in the investment business for more than 29 years, starting and financing growth companies in the United States, Europe, Israel and Asia.  Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA.  He began his investment career with TVM Techno Venture Management in Munich, Germany.  Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel.   Mr. Fleming is a director of Xencor (NASDAQ:  XNCR) and several private early stage life science companies.  He is also a director of Leerink Partners, a Boston based investment bank specializing in health care companies.  In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2003, where he co-teaches a class on business strategy for life science managers.  He is an advisor to the SBIR program of the National Cancer Institute.  Mr. Fleming holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs. E-mail

 


 

 

Advisors

Robert Kamen, Ph.D.

Dr. Kamen has more than 30 years of managerial experience in the biotechnology industry. He was president of the Abbott Bioresearch Center and on Abbott Pharmaceutical’s Executive Management Committee, after serving as BASF Bioresearch Corporation’s president before its acquisition by Abbott. His organization was responsible for the discovery and manufacture of Humira, the anti-TNF monoclonal antibody which is now the world’s top selling drug. Earlier he led research at Genetics Institute, Inc, one of the pioneering biotech companies. He is now an Entrepreneur in Residence with Third Rock Ventures and also serves on several biopharmaceutical company boards and scientific advisory panels. Dr. Kamen graduated from Amherst College with an A.B. (summa cum laude) in biophysics.  His doctoral studies at Harvard University in the laboratory of Prof. James D. Watson, resulted in a Ph.D. degree in biochemistry and molecular biology. After a post-doctoral fellowship at the University of Zürich, he moved to the Imperial Cancer Research Fund Laboratories, London, where he was head of its Transcription Laboratory. He is known for his fundamental contributions to the fields of gene expression, RNA stability, molecular virology, molecular oncology and human cytokines.

Brian Seed, Ph.D.

Brian Seed is a Professor of Genetics at Harvard Medical School and a member of the Center for Computational and Integrative Biology at Massachusetts General Hospital. His academic research has centered on the creation and exploitation of genetic selections that can be applied during the transient phase of expression of exogenous genes introduced into mammalian cells, as well as the study of signaling processes in the immune system. His recent interests lie in the identification of new approaches to therapeutic discovery for the creation of biologicals and small molecules that address societally important medical needs. Dr. Seed has been an advisor to large and small biopharmaceutical companies in the US and abroad for many years.  

Portfolio

ChunLab, based in Seoul, is a leading provider of advanced bioinformatics solutions for metagenomics and microbiome. ChunLab has the distinguished capabilities in NGS and content management to help support its global customers.
Corestem is a clinical stage biotechnology company based in Seoul, developing adult stem cell therapies to treat nervous system disorders such as ALS and Parkinson’s disease.
CrystalGenomics is a clinical stage small molecule drug company which is traded publicly in Korea (KOSDAQ: 083790). CG’s pipeline includes a tissue-specific NSAID for osteoarthritis, first-in-class antibiotic drug for drug resistant bacterial infection as well as epigenetics based anti-cancer therapies.

D&P Biotech, founded in 2006, is a spinout from the School of Medicine at Kyungpook National University and KIST. D&P develops a set of genomics prognostic tests to help manage the lung cancer.

Earlogic is a privately-held, revenue stage medical device and diagnostics company. It develops hearing-related solutions for diagnostics, restoration and conservation of hearing.

EuBiologics is a vaccines manufacturer. Its leading product is an orally available cholera vaccine currently under clinical development and will be provided to developing countries through foundation-sponsored programs. EuBiologics also provides a range of biologics CMO services to pharmaceutical clients.

Founded in 2010 in Seoul, Kang Stem Biotech is a clinical stage company which develops proprietary stem cell-based therapies to treat a range of autoimmune disorders.

Life Pack commercializes functional corrugated containers (based on its proprietary nano-technology) that effectively prolongs and protects freshness and integrity of the container’s content. Targeted markets include the agricultural, food and electronics industries.

Pathway Genomics is a revenue-stage genetic testing company located in San Diego. It offers genetic testing and personalized reports to help individuals proactively manage their health. Its tests sell internationally as well as domestically through B2B and B2C.

PCL is a development stage diagnostics company in Seoul. It develops protein-based chips for blood banks for screening of infectious pathogens. The same technology is used in the pharmaceutical industry for new target and drug discovery.

PharmAbcine is a privately-held clinical stage biotech company developing human therapeutic antibodies to treat cancer. Its leading program is targeted for glioma and additional research and preclinical programs include a range of first-in-class bi-specific antibodies.
Phyto Corporation is a development stage company that provides natural, low sodium organic salt. Its product has demonstrated favorable physiological effects and may offer a healthy alternative for salt and salt substitutes targeting the large global food and health food markets.
Zamat Medical is a privately-held company in Korea. It manufactures proprietary micro filter needles that reduce contamination risk during fluid and drug handling of ampoules and vials.
Technology Portfolio
Brinicle offers an integrated SNS and commerce experience through its proprietary Zero-Entry Point on the home screen of smartphones.
Technology Portfolio
N3N provides proprietary set of highly scalable delivery of images, control system solutions, visualization integration and operations analytics. N3N’s main customer is the Internet of Things industry.

Contact

Boston Office

One Broadway, 14th Floor, Cambridge, MA 02142, Tel (617)-577-3979, Fax (617)507-6363

Seoul Office

49F, 63-Building 60, Youido-dong, Yeongdeungpo-gu Seoul 150-763 Tel (Korea): +82-10-9483-5384